TerrAscend Corp. (OTCMKTS:TSNDF - Free Report) - Investment analysts at Atb Cap Markets cut their FY2025 earnings estimates for shares of TerrAscend in a research report issued on Monday, December 9th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings of ($0.13) per share for the year, down from their prior forecast of ($0.09). Atb Cap Markets has a "Hold" rating on the stock. The consensus estimate for TerrAscend's current full-year earnings is ($0.14) per share.
TerrAscend Trading Down 1.4 %
Shares of TSNDF traded down $0.01 during midday trading on Wednesday, hitting $0.75. The company had a trading volume of 149,367 shares, compared to its average volume of 339,766. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.35 and a quick ratio of 0.69. TerrAscend has a 52 week low of $0.66 and a 52 week high of $2.45. The company's 50 day moving average price is $0.99 and its 200 day moving average price is $1.23.
About TerrAscend
(
Get Free Report)
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names.
Featured Articles
Before you consider TerrAscend, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TerrAscend wasn't on the list.
While TerrAscend currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
